Phospho-TGFBR3 (T842) Antibody

What is Phospho-TGFBR3 (T842) antibody and what epitope does it recognize?

Phospho-TGFBR3 (T842) polyclonal antibody specifically recognizes the transforming growth factor beta receptor type III (TGFBR3, also known as betaglycan) only when phosphorylated at threonine 842. The antibody is typically raised in rabbits against a synthesized peptide derived from the human TGF beta Receptor III sequence surrounding the phosphorylation site of Thr842 (amino acid range: 801-850) . This specificity enables researchers to distinguish between phosphorylated and non-phosphorylated forms of TGFBR3, which is crucial for studying phosphorylation-dependent signaling events in the TGF-β pathway.

Which experimental applications is the Phospho-TGFBR3 (T842) antibody validated for?

The Phospho-TGFBR3 (T842) antibody has been validated for several key experimental applications including:

• Immunohistochemistry (IHC) at dilutions of 1/100 - 1/300

• Immunofluorescence (IF) at dilutions of 1/200 - 1/1000

• Enzyme-linked immunosorbent assay (ELISA) at dilutions of approximately 1/5000

When designing experiments, researchers should optimize these recommended dilutions for their specific experimental conditions, tissue types, and detection systems. Validation using appropriate positive and negative controls is essential for confirming antibody specificity in each application.

How should samples be prepared for optimal detection of phosphorylated TGFBR3?

For optimal detection of phosphorylated TGFBR3 (T842), implement the following methodological considerations:

• Preservation of phosphorylation status: Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in all buffers during sample preparation to prevent dephosphorylation events.

• Fixation for microscopy applications: For IHC and IF, use 4% paraformaldehyde fixation rather than alcohol-based fixatives that may affect phospho-epitope preservation.

• Antigen retrieval: Optimize antigen retrieval conditions (citrate buffer pH 6.0 or EDTA buffer pH 9.0) when using formalin-fixed paraffin-embedded tissues.

• Blocking strategy: Use phospho-blocking reagents that contain phosphoproteins to reduce background when detecting phospho-epitopes.

• Activation conditions: Consider activating cells with TGF-β ligand (5-10 ng/ml for 30-60 minutes) prior to lysis to increase phosphorylation signal at Thr842, particularly when studying induced phosphorylation events .

What controls should be included when using Phospho-TGFBR3 (T842) antibody in experimental designs?

A robust experimental design using Phospho-TGFBR3 (T842) antibody should include the following controls:

Additionally, comparing signals from phospho-specific antibodies with total TGFBR3 antibodies provides important normalization data to distinguish between changes in phosphorylation versus changes in total protein expression .

How can specificity of the Phospho-TGFBR3 (T842) antibody be validated in experimental systems?

Validating the specificity of Phospho-TGFBR3 (T842) antibody requires multiple complementary approaches:

• Phosphatase treatment: Treating duplicate samples with lambda phosphatase should eliminate signal from phospho-specific antibodies while preserving detection with total protein antibodies.

• Genetic manipulation: Utilizing CRISPR/Cas9 or siRNA to reduce TGFBR3 expression should proportionally reduce phospho-TGFBR3 signal.

• Mutagenesis validation: Expressing wild-type TGFBR3 versus T842A mutant constructs should demonstrate loss of phospho-antibody binding in the mutant while preserving detection with total TGFBR3 antibodies.

• Peptide competition: Pre-incubating the antibody with the phosphorylated immunogenic peptide should block specific binding.

• Induction studies: Stimulating cells with TGF-β should increase phospho-signal if the site is dynamically regulated by pathway activation .

What is the biological significance of TGFBR3 phosphorylation at Threonine 842?

Phosphorylation of TGFBR3 at Threonine 842 represents a critical regulatory mechanism in TGF-β signaling with several functional implications:

• Membrane localization and trafficking: Phosphorylation at T842 may regulate the subcellular localization of TGFBR3, affecting its availability at the cell membrane versus secreted compartments.

• Receptor shedding regulation: Phosphorylation status at T842 potentially modulates ectodomain shedding of TGFBR3, which produces soluble TGFBR3 that can sequester TGF-β ligands and modulate signaling activity .

• Signaling complex formation: The phosphorylation state likely influences interactions with type I and type II TGF-β receptors, affecting downstream SMAD-dependent and SMAD-independent signaling pathways.

• Tumor suppression activity: Given that TGFBR3 exhibits tumor suppressive functions in breast cancer and other malignancies, phosphorylation at T842 may regulate this activity through altered receptor function or interactions with signaling molecules .

The comprehensive understanding of T842 phosphorylation remains an active area of research, particularly regarding kinases responsible for this modification and its precise effects on receptor function.

How does TGFBR3 phosphorylation relate to cancer progression mechanisms?

TGFBR3 phosphorylation has significant implications for cancer progression through several mechanisms:

• Loss of tumor suppression: TGFBR3 demonstrates tumor suppressor functions in various cancers, with its expression frequently decreased during cancer progression. Loss of heterozygosity at the TGFBR3 locus occurs in approximately 50% of breast cancer cases, correlating with decreased TGFBR3 expression . Altered phosphorylation states may contribute to loss of this tumor suppressor function.

• Metastasis regulation: Restoration of TGFBR3 expression in breast cancer cells dramatically inhibits tumor invasiveness in vitro and tumor invasion, angiogenesis, and metastasis in vivo . The phosphorylation state of TGFBR3 at T842 may regulate these anti-metastatic properties.

• TGF-β sequestration: TGFBR3 undergoes ectodomain shedding to produce soluble TGFBR3, which binds and sequesters TGF-β to decrease TGF-β signaling . Phosphorylation may regulate this shedding process, thereby affecting the pro-tumorigenic or anti-tumorigenic effects of TGF-β signaling in a context-dependent manner.

• Prognostic implications: Low TGFBR3 levels predict decreased recurrence-free survival in breast cancer patients . Understanding TGFBR3 phosphorylation patterns could potentially provide additional prognostic information or therapeutic targets.

How does TGFBR3 phosphorylation integrate with canonical SMAD and non-canonical TGF-β signaling pathways?

TGFBR3 phosphorylation coordinates multiple facets of TGF-β signaling:

• Canonical SMAD pathway: While TGFBR3 is not directly required for SMAD2/3 phosphorylation, its phosphorylation state may modulate the efficiency of ligand presentation to type I and II receptors, indirectly affecting SMAD activation. Phosphorylated SMAD3 binds to SMAD4, leading to nuclear translocation and transcriptional regulation .

• PI3K-dependent signaling: TGF-β receptor signaling affects phosphorylation of the P85 subunit in the P85-P110 PI3K heterodimer. TGFBR3 phosphorylation may influence this process, potentially through altered receptor complex formation or downstream effector recruitment .

• SMAD-independent pathways: TGF-β can activate non-SMAD pathways including MAPK, Rho-like GTPases, and PI3K/AKT. TGFBR3 phosphorylation status may differentially regulate these pathways through altered protein-protein interactions or receptor compartmentalization.

• Cross-pathway regulation: In T cells, TGF-β receptor signaling affects PI3K activity and PtdIns levels, potentially through SMAD3-dependent mechanisms . TGFBR3 phosphorylation may contribute to this cross-regulation between signaling pathways.

How can phosphorylation at T842 be quantified relative to total TGFBR3 expression?

Quantifying the proportion of TGFBR3 phosphorylated at T842 relative to total TGFBR3 expression requires sophisticated methodological approaches:

• Western blot normalization: Perform parallel Western blots on the same samples using both phospho-specific and total TGFBR3 antibodies. Calculate the ratio of phospho-TGFBR3 to total TGFBR3 signal after densitometric analysis, ensuring both antibodies have comparable affinities or calibrating with recombinant standards.

• Flow cytometry analysis: Implement dual staining protocols where cells are fixed, permeabilized, and simultaneously or sequentially stained with fluorescently-labeled phospho-TGFBR3 and total TGFBR3 antibodies. This allows for single-cell analysis of phosphorylation rates.

• Immunoprecipitation-based quantification: Immunoprecipitate total TGFBR3 followed by immunoblotting with phospho-specific antibody, or vice versa, to determine the fraction of phosphorylated receptor.

• Mass spectrometry approaches: For absolute quantification, isotope-labeled peptide standards corresponding to both phosphorylated and non-phosphorylated forms of the T842-containing peptide can be used in mass spectrometry experiments to determine exact stoichiometry.

• Proximity ligation assay: This technique can visualize and quantify the co-localization of phospho-epitopes and total protein epitopes at the single-molecule level in fixed cells or tissues.

What kinases and phosphatases are implicated in regulating TGFBR3 phosphorylation at T842?

The regulation of TGFBR3 phosphorylation involves several enzymes:

• Candidate kinases:

  • Type II TGF-β receptor: May phosphorylate TGFBR3 as part of receptor complex formation, similar to its role in phosphorylating type I receptors .

  • Src family kinases: Known to phosphorylate other TGF-β receptor family members and could potentially target TGFBR3 .

  • PKA and PKC: These kinases have been implicated in phosphorylating various sites on TGF-β pathway components and may regulate TGFBR3 phosphorylation .

• Candidate phosphatases:

  • PPM1A/PP2Cα: Identified as a Smad2/3-specific phosphatase, it may also regulate receptor phosphorylation .

  • PP1c: Studies in Drosophila implicated PP1c in TGF-β receptor dephosphorylation, potentially through interaction with the SARA protein .

  • PTEN: Beyond its lipid phosphatase activity, PTEN has been shown to have functional interactions with TGF-β pathway components and may influence receptor phosphorylation states .

Future research using kinase and phosphatase inhibitors, genetic manipulation, and in vitro kinase/phosphatase assays will be necessary to definitively identify the enzymes regulating T842 phosphorylation.

How does TGFBR3 phosphorylation change during cellular differentiation and malignant transformation?

The dynamics of TGFBR3 phosphorylation during cellular state transitions reveal important regulatory principles:

What are common technical challenges when detecting phosphorylated TGFBR3 in clinical samples?

Researchers face several technical challenges when analyzing phosphorylated TGFBR3 in clinical specimens:

• Phospho-epitope preservation: Clinical samples often undergo delayed fixation or processing, leading to dephosphorylation by endogenous phosphatases. Implementation of rapid fixation protocols and phosphatase inhibitors during sample collection is critical.

• Antibody validation in human tissues: While the Phospho-TGFBR3 (T842) antibody shows reactivity with human samples , clinical specimens exhibit greater variability than controlled cell line experiments. Researchers should validate antibody performance on a subset of clinical samples before proceeding with large-scale studies.

• Quantification challenges: Clinical samples often display heterogeneous cell populations with variable TGFBR3 expression and phosphorylation. Consider using multiplex immunofluorescence approaches that allow simultaneous detection of cell type markers, total TGFBR3, and phospho-TGFBR3.

• Low abundance issues: TGFBR3 expression decreases during cancer progression , potentially making phospho-TGFBR3 difficult to detect in advanced tumors. Signal amplification methods such as tyramide signal amplification may be necessary.

• Contextual interpretation: Phosphorylation status must be interpreted in relation to total protein expression, TGF-β ligand availability, and pathway activity markers. Develop multiplex assessment strategies that evaluate these parameters simultaneously.

How can inconsistent Phospho-TGFBR3 (T842) antibody performance be addressed in experimental settings?

When encountering inconsistent antibody performance, implement these systematic troubleshooting approaches:

• Antibody storage and handling: Ensure proper aliquoting and storage at -20°C in 50% glycerol buffer as recommended . Avoid repeated freeze-thaw cycles which can degrade antibody performance.

• Sample preparation optimization:

  • Verify phosphatase inhibitor efficacy with positive controls

  • Test multiple lysis buffers to identify optimal extraction conditions

  • Adjust protein concentration to ensure detection within the antibody's linear range

• Protocol modifications:

  • For Western blotting: Test different blocking agents (BSA vs. milk), membrane types (PVDF vs. nitrocellulose), and detection systems

  • For IHC/IF: Optimize antigen retrieval conditions, incubation times, and detection methods

• Validation strategies:

  • Compare results from multiple antibody lots

  • Validate with alternative detection methods (e.g., mass spectrometry)

  • Implement genetic controls (TGFBR3 knockdown/knockout)

• Standardization practices:

  • Include consistent positive controls across experiments

  • Develop standard operating procedures with detailed protocol documentation

  • Consider using recombinant phosphorylated protein standards for calibration

What strategies can address signal interference when studying TGFBR3 phosphorylation in complex signaling environments?

When investigating TGFBR3 phosphorylation within complex signaling networks, researchers can implement these approaches to minimize interference:

• Temporal resolution strategies:

  • Perform detailed time-course experiments to distinguish primary from secondary phosphorylation events

  • Use rapid pathway inhibition (e.g., small molecule inhibitors) to identify direct regulatory relationships

• Pathway dissection approaches:

  • Employ selective pathway inhibitors to isolate contributions from specific signaling cascades

  • Use genetic approaches (CRISPR screens, kinase libraries) to systematically identify pathway components affecting TGFBR3 phosphorylation

• Single-cell analysis methods:

  • Implement phospho-flow cytometry or mass cytometry to assess phosphorylation at the single-cell level

  • Consider spatial analysis techniques like imaging mass cytometry to preserve tissue context

• Computational deconvolution:

  • Apply multivariate statistical methods to distinguish TGFBR3 phosphorylation patterns from background signaling

  • Develop machine learning approaches to identify signature patterns associated with specific pathway activations

• Model system simplification:

  • Use reconstitution experiments in minimal cellular backgrounds (e.g., TGFBR-null cells with controlled receptor expression)

  • Employ in vitro kinase assays with purified components to establish direct relationships